Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men

FAST AND ROBUST SEGMENTATION AND CLASSIFICATION FOR CHANGE DETECTION IN URBAN POINT CLOUDS

Change detection is an important issue in city monitoring to analyse street furniture, road works, car parking, etc. For example, parking surveys are needed but are currently a laborious task involving sending operators in the streets to identify the changes in car locations. In this paper, we propose a method that performs a fast and robust segmentation and classification of urban point clouds, that can be used for change detection. We apply this method to detect the cars, as a particular object class, in order to perform parking surveys automatically. A recently proposed method already addresses the need for fast segmentation and classification of urban point clouds, using elevation images. The interest to work on images is that processing is much faster, proven and robust. However there may be a loss of information in complex 3D cases: for example when objects are one above the other, typically a car under a tree or a pedestrian under a balcony. In this paper we propose a method that retain the three-dimensional information while preserving fast computation times and improving segmentation and classification accuracy. It is based on fast region-growing using an octree, for the segmentation, and specific descriptors with Random-Forest for the classification. Experiments have been performed on large urban point clouds acquired by Mobile Laser Scanning. They show that the method is as fast as the state of the art, and that it gives more robust results in the complex 3D cases.</jats:p

FAST AND ROBUST SEGMENTATION AND CLASSIFICATION FOR CHANGE DETECTION IN URBAN POINT CLOUDS

Change detection is an important issue in city monitoring to analyse street furniture, road works, car parking, etc. For example, parking surveys are needed but are currently a laborious task involving sending operators in the streets to identify the changes in car locations. In this paper, we propose a method that performs a fast and robust segmentation and classification of urban point clouds, that can be used for change detection. We apply this method to detect the cars, as a particular object class, in order to perform parking surveys automatically. A recently proposed method already addresses the need for fast segmentation and classification of urban point clouds, using elevation images. The interest to work on images is that processing is much faster, proven and robust. However there may be a loss of information in complex 3D cases: for example when objects are one above the other, typically a car under a tree or a pedestrian under a balcony. In this paper we propose a method that retain the three-dimensional information while preserving fast computation times and improving segmentation and classification accuracy. It is based on fast region-growing using an octree, for the segmentation, and specific descriptors with Random-Forest for the classification. Experiments have been performed on large urban point clouds acquired by Mobile Laser Scanning. They show that the method is as fast as the state of the art, and that it gives more robust results in the complex 3D cases

EXPERIMENTAL ASSESSMENT OF THE QUANERGY M8 LIDAR SENSOR

In this paper, some experiments with the Quanergy M8 scanning LIDAR system are related. The distance measurement obtained with the Quanergy M8 can be influenced by different factors. Moreover, measurement errors can originate from different sources. The environment in which the measurements are performed has an influence (temperature, light, humidity, etc.). Errors can also arise from the system itself. Then, it is necessary to determine the influence of these parameters on the quality of the distance measurements. For this purpose different studies are presented and analyzed. First, we studied the temporal stability of the sensor by analyzing observations during time. Secondly, the assessment of the distance measurement quality has been conducted. The aim of this step is to detect systematic errors in measurements regarding the range. Differents series of measurements have been conducted : at different range and in diffrent conditions (indoor and outdoor). Finally, we studied the consistency between the differents beam of the LIDAR.</jats:p

EXPERIMENTAL ASSESSMENT OF THE QUANERGY M8 LIDAR SENSOR

In this paper, some experiments with the Quanergy M8 scanning LIDAR system are related. The distance measurement obtained with the Quanergy M8 can be influenced by different factors. Moreover, measurement errors can originate from different sources. The environment in which the measurements are performed has an influence (temperature, light, humidity, etc.). Errors can also arise from the system itself. Then, it is necessary to determine the influence of these parameters on the quality of the distance measurements. For this purpose different studies are presented and analyzed. First, we studied the temporal stability of the sensor by analyzing observations during time. Secondly, the assessment of the distance measurement quality has been conducted. The aim of this step is to detect systematic errors in measurements regarding the range. Differents series of measurements have been conducted : at different range and in diffrent conditions (indoor and outdoor). Finally, we studied the consistency between the differents beam of the LIDAR

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

International audienceInterindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men

Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

Aims to compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in patients presenting within 6 h of onset of ST elevation acute myocardial infarction. Methods and Results 15 078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg-1 as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. Conclusion Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration. (C) 2000 The European Society of Cardiology

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)